Proactive accounting: a key factor in the success of biotechnology startups
Article Abstract:
Entrepreneurs neglect the accounting and financial issues in the early part of the development, because of their focus on key priorities like product development and corporate financing. Proactive approach to accounting and financial management can build trust with customers, investors, and partners.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Is repugnance wise? Visceral responses to biotechnology
Article Abstract:
Things, which are repugnant, will make one turn away in disgust. Many individuals are reluctant to link disgust to the study of ethical issues in biotech, whereas many scientists attend to the moral significance of revulsion.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Strategic HR for today's biotechnology companies
Article Abstract:
The HR must be a true business partner to succeed in the biotechnology industry. The fundamental issues of HR are the efforts to achieve excellence through focus on learning, quality, teamwork and reengineering.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Push here for fun. The latest in validator technology. Dance to the music
- Abstracts: Scripps lured to Sunshine State. Companies jostle for access to public markets. Increasing number of companies found ineligible for SBIR funding
- Abstracts: Turning a footnote into a headache. The squeeze is on: will it be enough to tank profits?
- Abstracts: Integrative model of the response of yeast to osmotic shock. Principles of transcriptional control in the metabolic network of Saccharomyces cerevisiae
- Abstracts: Biotech holds steady in Q4. Any diamonds in the diagnostic coal? Celltech acquisition sends mixed messages